News Story: Full Text
Sponsored By
Cedars-Siani Medical Center Brain Tumor Program
Please Click On The Above Banner For More Details
Braintumor Website


The course of neurocognitive functioning in high-grade glioma patients


Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)



Website: http://neuro-oncology.dukejournals.org/cgi/content/abstract/15228517-2006-012v1

Posted on: 11/22/2006

First published on October 3, 2006
Neuro-oncol 2006, DOI:10.1215/15228517-2006-012
© Copyright 2006 by the Society for Neuro-Oncology

Received December 9, 2005
Accepted April 25, 2006

Clinical Investigations

The course of neurocognitive functioning in high-grade glioma patients

Ingeborg Bosma 1*, Maaike J. Vos 1, Jan J. Heimans 1, Martin J.B. Taphoorn 2, Neil K. Aaronson 3, Tjeerd J. Postma 1, Henk M. van der Ploeg 4, Martin Muller 3, W. Peter Vandertop 5, Ben J. Slotman 6, Martin Klein 4

1 Department of Neurology, VU University Medical Center, 1081 HV Amsterdam, The Netherlands
2 Department of Neurology, Medical Center Haaglanden, 2501 CK The Hague, and University Medical Center Utrecht, 3508 GA Utrecht, The Netherlands
3 Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands
4 Department of Medical Psychology, VU University Medical Center, 1081 HV Amsterdam, The Netherlands
5 Department of Neurosurgery, VU University Medical Center, 1081 HV Amsterdam, The Netherlands
6 Department of Radiation Oncology, VU University Medical Center, 1081 HV Amsterdam, The Netherlands

 

* To whom correspondence should be addressed. E-mail: i.bosma@vumc.nl .


   Abstract

We evaluated the course of neurocognitive functioning in newly diagnosed high-grade glioma patients and specifically the effect of tumor recurrence. Following baseline assessment (after surgery and before radiotherapy), neurocognitive functioning was evaluated at 8 and 16 months. Neurocognitive summary measures were calculated to detect possible deficits in the domains of (1) information processing, (2) psychomotor function, (3) attention, (4) verbal memory, (5) working memory, and (6) executive functioning. Repeated-measures analyses of covariance were used to evaluate changes over time. Thirty-six patients were tested at baseline only. Follow-up data were obtained for 32 patients: 14 had a follow-up at 8 months, and 18 had an additional follow-up at 16 months. Between baseline and eight months, patients deteriorated in information-processing capacity, psychomotor speed, and attentional functioning. Further deterioration was observed between 8 and 16 months. Of 32 patients, 15 suffered from tumor recurrence before the eight-month follow-up. Compared with recurrence-free patients, not only did patients with recurrence have lower information-processing capacity, psychomotor speed, and executive functioning, but they also exhibited a more pronounced deterioration between baseline and eight-month follow-up. This difference could be attributed to the use of antiepileptic drugs in the patient group with recurrence. This study showed a marked decline in neurocognitive functioning in HGG patients in the course of their disease. Patients with tumor progression performed worse on neurocognitive tests than did patients without progression, which could be attributed to the use of antiepileptic drugs. The possibility of deleterious effects is important to consider when prescribing antiepileptic drug treatment.

Key Words: high-grade glioma, neurocognitive functioning, neuropsychological assessment, tumor recurrence, prospective study




Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740